SUMOylation Connects Cell Stress Responses and Inflammatory Control: Lessons From the Gut as a Model Organ

Jörn Karhausen 1,2*, Luis Ulloa 1 and Wei Yang 1*

1 Department of Anesthesiology, Center for Perioperative Organ Protection, Duke University Medical Center, Durham, NC, United States, 2 Department of Pathology, Duke University Medical Center, Durham, NC, United States

Conjugation with the small ubiquitin-like modifier (SUMO) constitutes a key post-translational modification regulating the stability, activity, and subcellular localization of its target proteins. However, the vast numbers of identified SUMO substrates obscure a clear view on the function of SUMOylation in health and disease. This article presents a comprehensive review on the physiological relevance of SUMOylation by discussing how global SUMOylation levels—rather than specific protein SUMOylation—shapes the immune response. In particular, we highlight the growing body of work on SUMOylation in intestinal pathologies, because of the unique metabolic, infectious, and inflammatory challenges of this organ. Recent studies show that global SUMOylation can help restrain detrimental inflammation while maintaining immune defenses and tissue integrity. These results warrant further efforts to develop new therapeutic tools and strategies to control SUMOylation in infectious and inflammatory disorders.

Keywords: small ubiquitin like modifier, post-translational modification, cell stress response, adaptive response mechanism, intestinal pathologies

INTRODUCTION

Post-translational modifications (PTMs) form a crucial layer of regulation that substantially increases the functional repertoire of the existing proteome. One critical example is small ubiquitin-like modifier (SUMO) modification (SUMOylation), in which SUMO is covalently, but reversibly, linked to the lysine residues of target proteins. Because SUMOylation is highly responsive to endogenous and environmental stressors and because a large number of SUMO targets are transcription factors or nuclear proteins, this PTM is increasingly recognized as a key regulator in health and disease (1–3). Current literature on SUMOylation remains confusing, as pathways can be SUMOylated at multiple sites with seemingly conflicting consequences for its activity. What is striking, however, is that, following cell stress, SUMOylation rapidly increases across a broad set of target proteins and effectively re-programs cellular responses. This review summarizes the emerging knowledge of how this global SUMOylation response helps maintain cellular and tissue integrity by preventing exaggerated inflammation.

THE SUMO PATHWAY

Mammalian cells express 4 SUMO isoforms: SUMO1, SUMO2, SUMO3, and a less-studied SUMO4 [for detailed review of the SUMO pathway refer to (1, 4)]. Whereas, SUMO1 shares about 50%
SUMOylation connects cell stress to major inflammatory pathways

Various works have outlined SUMOylation as an important stress response conserved through evolution (10–13). These studies established that SUMOylation orchestrates cellular responses to heat shock, DNA damage, and mitochondrial-, oxidative-, hypoxic-, and ethanol stress (12–16). Inflammation is a primary response to stress. While allowing for resolving infection and removing cellular debris, exaggerated inflammation directly threatens tissue integrity. Recent studies reveal a critical role of SUMOylation in both innate and adaptive immunity and provide a link between cellular stress sensing and inflammatory responses (17). However, a fundamental problem is that SUMOylation modulates often multiple and contradictory decision points within key inflammatory pathways, which leads to an inconsistent understanding of its true physiologic role. For example, NF-κB pathway activity is inhibited by SUMOylation at multiple levels, i.e., by stabilizing IκB and maintaining NF-κB repression (18); by interfering with the binding of co-activator CBP (19, 20); by transrepression of inflammatory target genes (21–24); and by regulating the stability of early response gene products such as the Nuclear receptor NR4A1 (25). However, SUMOylation can also stimulate NF-κB through de-repression of the negative regulators TANK (26) and NEMO (27). As a consequence, modulating SUMOylation has yielded conflicting results regarding NF-κB activity and inflammatory outcomes.

As such, the SUMO E3 ligase protein inhibitor of activated STATs (PIAS) can inhibit NF-κB activation in some models (19, 28–32), but can also activate NF-κB after genotoxic stress (33). SENP2, which is particularly responsive to genotoxic stimuli, efficiently de-SUMOylates NEMO and limits NF-κB-dependent cell survival responses (34, 35). Correspondingly, depletion of SENP6 potentiates NF-κB-mediated induction of proinflammatory genes after endotoxin exposure in vitro and in vivo (36); however, endothelial knock-out of SENP1 in aortic grafts achieves the opposite and blunts endothelial responses to TNFα or IL-1β (37).

Another example of seemingly conflicting SUMOylation effects was observed in the regulation of NLRP3 activity. Here, Barry et al. (38) demonstrated that SUMO2/3 modification of NLRP3 at multiple lysine residues inhibits NLRP3 activation, whereas, stimulation-dependent NLRP3 de-SUMOylation through SENP6 and SENP7 promotes NLRP3 activation. However, NLRP3 modification with SUMO1 at one of these sites induces opposite results and promotes inflammasome activation and IL-1β secretion, which is reversed by de-SUMOylation with SENP3 (39).

Changes in global SUMOylation levels reprogram inflammatory responses

As outlined above, effects of SUMOylation on individual target proteins and pathways are complex and likely highly context-dependent. However, a striking observation under cell-stress conditions is the rapid net increase of SUMOylated proteins (16, 40–42). For the SUMO2/3 isoforms, this increase is readily appreciated by the detection of a high-molecular “smear”—a broad signal representing the large variety of SUMOylated proteins of different sizes—in Western blots (and the parallel decrease of un-bound SUMO2/3). A consistent body of evidence is emerging that identifies this increase of global SUMOylation as a broad-acting, adaptive response controlling inflammation. The consequences of rapid changes in cellular SUMOylation levels on inflammatory responses have not been comprehensively reviewed, and we will therefore summarize the available data produced by modifying global SUMOylation (predominantly by targeting the key E2-conjugase, Ubc9) and de-SUMOylation (by targeting different SENPs).

Global SUMOylation and the control of immune cell functions

Deque et al. demonstrated that Ubc9 null dendritic cells (DCs) responded to LPS with enhanced recruitment of RNA polymerase II to LPS-induced genes and consequently, with an exacerbated production of pro-inflammatory cytokines (43). Interestingly, this work also revealed that SUMOylation repressed LPS-induction of interferon-β (IFNβ1) and thus inhibited the crosstalk between type I IFN and pattern recognition receptor-ligand responses. In chimeric animals that received Ubc9-null bone marrow, these findings translated into
an increased susceptibility to endotoxin shock, but resistance to viral infection, indicating that global SUMOylation effectively limits inflammation-induced pathology.

This anti-inflammatory role of SUMOylation is further supported by evolving evidence from studies using pharmacologic approaches. For example, the highly selective SUMOylation inhibitor TAK981—a new drug currently investigated as an adjuvant treatment of malignancies—prevents SUMOylation by inhibiting the transfer of SUMO to the E2 conjugating enzyme Ubc9 (44). In mouse bone-marrow and human peripheral blood mononuclear cell-derived DCs, TAK981 induces cell activation and maturation, triggers the production of inflammatory cytokines, and enhances priming and activation of antigen-reactive cytotoxic T cells. Notably, some of these effects were reversed by blocking interferon signaling (45). Conversely, we recently found that the synthetic organoselenium compound, ebelsen, increases global SUMOylation levels by inhibiting SENP2 (46)—a protease with high catalytic activity for SUMO2/3 (47). Interestingly, ebelsen has been shown to inhibit both DC-induced cytokine production by T cells and T cell-induced cytokine production by DCs (48).

Moreover, studies based on genetic modification of the SUMO pathway not only reveal the critical involvement of SUMOylation in the development and activity of lymphoid cells, mainly T cells, but also demonstrate its anti-inflammatory function. SENP1 is highly expressed at the early stages of T and B cell development and Senp1-null mice exhibit impairment specifically of T and B cell development (49). However, SUMOylation also modulates T cell activation by regulating T cell receptor (TCR)-signaling. TCR induces SUMO1 conjugation to control proximal (e.g., assembly of TCR with coreceptors) (50, 51) and distal [e.g., activation of Nuclear factor of activated T-cells (NFAT)] (52) signaling events, and mutation of the SUMOylation sites impairs cell activation and Th2 differentiation in primary CD4+ T cells and T cell lines. Along these lines, emerging data suggests that SUMO inhibition of T cells isolated from chronic lymphatic leukemia (CLL) patients, shifts the T cell balance toward Th1 polarization (53). Together, this could indicate that global SUMOylation is a critical determinant of the Th1/Th2 balance, which is further supported by a clear role of SUMOylation in supporting the number and functions of regulatory T cells (Treg), a specialized, inhibitory CD4+ T cell subtype. Here, pharmacologic inhibition of SUMOylation impairs Treg polarization in isolated CD4+ T cells (53), and Treg-specific Ubc9 deletion impairs TCR-driven Treg proliferation and activation, and reproduces in animals the severe autoimmune phenotype seen with Foxp3 deletion (54). Consistent with this, Ubc9 deletion in macrophages attenuates the M2 (anti-inflammatory) program and reduces their capacity to induce Treg differentiation (55).

Studies of SUMOylation in other immune cells revealed that increased CD45 SUMOylation in Senp1-deficient mice promotes myeloid-derived suppressor cells (MDSC) immunosuppression function (56). Furthermore, siRNA knock-down of either SUMO1 or Ubc9 increases reactive oxygen species production from NADPH oxidases in neutrophils, whereas SUMO1 overexpression induces the opposite effect. This suggests that SUMOylation may control the ability of neutrophils to cause tissue injury or kill pathogens (57). Together, we have highlighted the diverse inflammation-regulatory effects of global SUMOylation in specific immune cell populations. To better understand how changes of global SUMOylation levels affect tissue outcomes in inflammation, we will next focus on studies that examined modulated SUMOylation levels in pre-clinical disease models.

GLOBAL SUMOYLATION CONTROLS TISSUE INFLAMMATION: LESSONS FROM THE GUT AS A MODEL ORGAN

Parenchymal cells react to injurious stimuli with a complex and often interrelated set of inflammatory and adaptive responses. In balancing the needs of pathogen and cell debris removal (inflammation) and preservation of cellular function under adverse conditions (adaptation), control of the immune environment is essential. This holds especially true for the gut, where the intestinal epithelium forms a single barrier between trillions of bacteria and an enormous mass of immune cells harbored within the intestinal walls. Because adverse environmental conditions constantly threaten epithelial integrity (58), adaptive responses are particularly well-developed in the gut (59–61). Indeed, the work of Demarque et al. impressively showed in inducible Ubc9-knockout mice that SUMOylation is crucial to intestinal maintenance through ensuring organized cell-renewal and differentiation, and by controlling mechanical stability of the epithelial monolayer (62). Together, this highlights the intestine as a model organ to study how SUMOylation regulates inflammation in an environment particularly challenged by metabolic, inflammatory, and infectious stressors.

SUMO and Metabolic Stress

Epithelial functions generate substantial metabolic demands (63). Together with a vascular supply prone to shunting oxygen-rich blood away from the villus tip, this renders the intestinal epithelium particularly sensitive to reductions in blood flow and resultant ischemia/hypoxia (59). Interestingly, we found that SUMO2/3-conjugation, while highly responsive to perfusion abnormalities (64–66), did not follow the crypt-to-villus oxygen gradient (59), nor the matching expression of hypoxia-adaptive responses such as HIF-1α (67), but was restricted to villus crypt epithelia. However, intestinal ischemia/reperfusion (I/R) caused the rapid expansion of SUMO2/3 signal into villus tip epithelia establishing the stress-responsiveness of SUMO2/3 conjugation. This is an adaptive response, as demonstrated in Ubc9 transgenic animals. In these animals, increased SUMOylation had a major effect on transcriptional responses regulating inflammatory cell recruitment pathways. Consistent with the dramatic reduction of neutrophil influx and the improved preservation of intestinal architecture in Ubc9 transgenic animals after I/R, we found that pathways regulating inflammatory cell adhesion, tissue integrity and production of chemotactic factors were broadly modified in both whole tissue samples and in epithelia (42). Of note, compensatory overexpression of SUMO2/3 isoform in
Sumo1 null mice led to a comparable protective phenotype as observed in Ubc9 transgenic animals. Together, our data identify SUMOylation as a powerful mechanism by which the intestine controls the inflammatory environment during metabolic stress and highlights the particular importance of the SUMO2/3 isoforms in stress-adaptive, anti-inflammatory protection.

**SUMO in Inflammatory Bowel Diseases (IBD)**

The noted prominent regulation of inflammatory responses raises the question of the role of SUMOylation in primary inflammatory diseases. Indeed, metabolic stress and dysregulated inflammation are key features of IBD (59, 68) and create conditions known to strongly induce SUMO2/3 conjugation (40, 41). Transcriptional analysis from Ubc9 transgenic mice after I/R revealed a broad suppression of chemotactic factor expression, with many of them implicated in IBD pathogenesis [CXCL9 (69), CXCL16 (70), CCL20 (71), IL17A (72), IL27 (73)]. For example, IL17A is a cytokine that can amplify inflammation by stimulating production of inflammatory mediators and thus promotes the recruitment of neutrophils and monocytes (74). IL17A has been implicated in many inflammatory diseases, including IBD (75). Singh et al. recently demonstrated that SUMOylation of ROR-γt—a key transcriptional regulator of IL17A—represses IL17A transcription (76). As a consequence, mice receiving Th17 cells expressing a SUMOylation-deficient mutant of ROR-γt in an adoptive transfer colitis model had significantly worse disease outcome measures compared to mice receiving Th17 cell expressing wild-type ROR-γt.

Surprisingly, while inflammatory processes such as rheumatoid arthritis (77–79) or I/R increase SUMOylation levels (42, 65, 80), Musta et al. reported the downregulation of Ubc9 and, with it, decreased SUMO-conjugation levels in the gut of murine and human IBD (81). This unexpected finding needs to be further confirmed in the context of disease stages and cell populations. Nonetheless, consistent with an anti-inflammatory function of SUMOylation, RNAi-knockdown of Ubc9 in cultured human epithelial cells significantly altered inflammatory gene expression, including that of key pro-inflammatory regulators RelA, cFos, and cJun. Furthermore, the level of Ubc9 downregulation correlated in both mouse and clinical samples with disease severity and the tissue expression of inflammatory cytokines (81). Following this logic, the same group developed a nanogel DNA delivery system to induce intestinal SUMOylation by enhancing expression of the E3 ligase, Pias1 (protein inhibitor of activated STAT1) (82). These studies together support that increasing tissue SUMOylation blunts inflammation and tissue disruption in the gut.

**SUMO and Pathogen Responses**

Growing evidence indicates that SUMOylation levels define the balance between destructive inflammation and effective defenses against pathogens within the gut. For example, *Shigella flexneri*, the etiological agent of bacterial dysentery, attacks colonic epithelia and causes massive inflammation-induced damage. Notably, mice haploinsufficient for Ubc9, display a hyper-invasive and hyper-inflammatory phenotype upon *in vivo* infection, emphasizing the importance of SUMOylation in the maintenance of intestinal permeability and mucosal inflammation (83). SILAC-based proteomics analysis revealed that invasive (vs. non-invasive) Shigella infection generally caused a reduction of SUMO2 modification. This affected a defined functional network of transcriptional regulators, where Shigella-induced changes in SUMOylation of regulators such as c-FOS, PPARc, and RXRα (24, 84, 85) were predicted to favor inflammation.

In line with this, SUMOylation is emerging as a key modulator of multiple host-pathogen interactions, with various pathogens actively targeting SUMOylation to their advantage. As such, *Listeria monocytogenes*, *Clostridium perfringens*, and *Streptococcus pneumoniae* induce proteasome-independent degradation of Ubc9 through closely related virulence factors (86), while *Shigella flexneri* targets the E1 ligase UBE2/SAE2 via proteasomal degradation (87), and *Salmonella Typhimurium* targets Ubc9 via miRNA-mediated down-regulation (88). This attention given by bacterial (89), viral (90), and fungal (91) pathogens to the SUMO pathway highlights the critical role of this pathway in ensuring a balanced inflammatory response.

**PERSPECTIVES**

In summary, mounting evidence supports global SUMOylation as a crucial cell stress response regulating inflammation. However, the appraisal of specific connections within this SUMO interactome remains complex, as SUMOylation of multiple components within a single pathway can produce contradictory effects. While this may serve to fine-tune specific responses in certain settings, it leaves unclear what is the actual impact of SUMOylation in diseases. Using the growing body of evidence from the gut as a model organ of particular metabolic, inflammatory, and infectious challenges (*Figure 1*), we further establish the notion that the global increase of SUMOylation during cellular stress constitutes a coordinated response to limit inflammation and preserve cellular and tissue integrity.

Many aspects of this response are still unclear. First and foremost, whether global increase of SUMOylation after cell stress is the equivalent of a flooding of the system with SUMO modifications, or rather the wide-sweeping but targeted introduction of a specific set of protein modifications. In line with this question, it remains unknown how SUMOylation itself is regulated following cell stress. The speed of the response (minutes *in vitro*) suggests a predominantly post-translational regulation of SUMO pathway components. Indeed, hypoxia-stimulated SUMOylation was not linked to increased expression of SUMO1, SUMO2, or SUMO3 by proteome or mRNA analysis but rather to the reversible inhibition of the catalytic activity, particularly of SENP1 and SENP3 (16). Yet overall, the decision points that trigger the increase of SUMOylation levels on such a grand scale remain to be determined.

Another fundamental consideration is the specific role of SUMO1 vs. SUMO2/3 in regulating inflammation during cell stress. Initial SUMO research focused on SUMO1 conjugation,
yet growing evidence highlights the quick response of SUMO2/3 conjugation to cellular stressors, and the distinct roles of the SUMO isoforms. For example, NLRP3 is differentially regulated by SUMO1 vs. SUMO2/3 as discussed above (38, 39), while non-canonical type I interferon responses appear to be regulated by SUMO2/3, but not by SUMO1 (93). Similarly, our studies of SUMOylation in the gut also reveal that this process may play a distinct role in different cell populations (42). Consequently, studies of whole tissues, particularly within complex organs such as the gut, may yield conflicting results on how SUMOylation changes and affects inflammation. These results suggest a highly nuanced SUMO regulation, and future research will need to better determine isoform-specific and cell type-specific effects. A recently developed Sumo2 conditional knockout mouse strain could be an invaluable tool (94).

Ultimately, to harness the beneficial potential of global SUMOylation, e.g., in autoimmune diseases, new pharmacologic interventions are needed. Here, oncology research has provided us with a number of specific SUMO inhibitors (95), but similar efforts are now needed to identify effective SUMO activators (46). Such studies can build on the presented evidence in multiple inflammatory disorders including I/R (42), IBD (82), and infectious disorders (83), which identify SUMOylation as a therapeutic target to restrain detrimental inflammation while maintaining immune defenses.

**AUTHOR CONTRIBUTIONS**

JK and WY developed the concept. All authors wrote and edited the final version of the manuscript.

**FUNDING**

This work was funded by American Heart Association (AHA) Grant 19IPLOI34760123, a Duke School of Medicine Health Scholar Award and a Roizen Anesthesia Research Foundation Grant from the Society of Cardiovascular Anesthesiologists (to JK) and AHA Grant 18CSA34080277 and NIH Grant NS099590 (to WY).

**ACKNOWLEDGMENTS**

The authors thank Sara Galletti, PhD for editorial support.
gene-expression programs during innate sensing. Nat Immunol. (2016) 17:140–9. doi: 10.1038/ni.3342

44. National Cancer Institute. Sumoylation Inhibitor TAK-981. Available online at: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/subumstat (accessed February 6, 2021).

45. Khattar M, Song K, Grossman S, Xega K, He X, Idamakanti N, et al. Tak981: A first in class sumo inhibitor in phase 1 trials that promotes dendritic cell activation, antigen-presentation, and t cell priming [abstract]. Cancer Res. (2019) 79:Abstract nr 3252. doi: 10.1158/1535-7445.AM2019-3252

46. Bernstock JD, Ye D, Smith JA, Lee YJ, Gessler FA, Yasgar A, et al. Quantitative high-throughput screening identifies cytoprotective molecules that enhance sumo conjugation via the inhibition of sumo-specific protease (senp2). FASEB J. (2017) 32:1677–91. doi: 10.1096/fj.201700711R

47. Karhausen J, Haase VH, Colgan SP. Inflammatory hypoxia: role of hypoxia-inducible factor-1 in intestinal homeostasis and inflammation. J Cell Biol. (2016) 45:21–21. doi: 10.1096/jbc.M115603207

48. Wang Z, Wang R, Sheng H, Sheng SP, Paschen W, Yang W. Transient ischemia induces massive nuclear accumulation of sumo2/3-conjugated proteins in spinal cord neurons. Spinal Cord. (2013) 51:139–43. doi: 10.1038/sc.2012.100

49. Van Nguyen T, Angkasekwinai P, Dou H, Lin FM, Lu LS, Cheng J, et al. Sumoylation pathway alteration coupled with downregulation of sumo2 enzyme at mucosal epithelium modulates inflammation in inflammatory bowel disease. J Mol Med (Berl). (2019) 97:905–13. doi: 10.1007/s00109-017-1544-2

50. Schroepf S, Kappler R, Brand S, Prell C, Lohse J, Gläs J, et al. Strong overexpression of ccrx3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis. (2010) 16:1882–90. doi: 10.1002/ibd.21312

51. Uza N, Nakase H, Yamamoto S, Yoshino T, Takeda Y, Ueno S, et al. Sr-psox/cxcl16 plays a critical role in the progression of colonic inflammation. Gut. (2011) 60:494–505. doi: 10.1136/gut.2010.221879

52. Lao M, Zhang Z, Li N, Xu S, Shi M, Zou Y, et al. Role of small ubiquitin-modifying enzymes regulates the microcluster assembly and physiological function of PLC-γ1. Spinal Cord. (2019) 57:315–26. doi: 10.1007/s00385-016-1221-1

53. Andrews C, McLean MH, Durum SK. Interleukin-27 as a novel therapy for inflammatory bowel disease: a critical review of the literature. Inflamm Bowel Dis. (2016) 22:2255–64. doi: 10.1097/MIB.0000000000000818

54. Amatyia N, Garg AV, Gaffen SL. Il-17 signaling: the yin and the yang. Trends Immunol. (2017) 38:310–22. doi: 10.1016/j.it.2017.01.006

55. Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity. (2015) 43:104–51. doi: 10.1016/j.immuni.2015.12.003

56. Singh AK, Khare P, Obaid A, Conlon KP, Barvur V, DePeinio RA, et al. Regulation of matrixmetalloproteinase-3 and matrixmetalloproteinase-13 by sumo-2/3 through the transcription factor nf-κb. Ann Rheum Dis. (2016) 25:3065–70. doi: 10.1136/annrheumdis-2016-212836

57. Mani A, Han Z, Li N, Xu S, Shi M, Zou Y, et al. Role of small ubiquitin-like modifier proteins-1 (sumo-1) in regulating migration and invasion of fibroblast-like synovcytes from patients with rheumatoid arthritis. Exp Cell Res. (2019) 375:52–61. doi: 10.1016/j.yexcr.2018.12.011

58. Wang C, Xiao Y, Lao M, Wang J, Xu S, Li R, et al. Increased sumo-activating enzyme sae1/ubap2 promotes glycolysis and pathogenic behavior of rheumatoid fibroblast-like synovcytes. JCI Insight. (2020) 5:135935. doi: 10.1172/jci.insight.135935

59. Frank S, Peters MA, Wehmeyer C, Strieholt S, Koers-Wunrau C, Bertrand J, et al. Regulation of matrixmetalloproteinase-3 and matrixmetalloproteinase-13 by sumo-2/3 through the transcription factor nf-κb. Ann Rheum Dis. (2013) 72:1874–81. doi: 10.1136/annrheumdis-2012-202080

60. Guo C, Wei Q, Su Y, Dong Z. Sumoylation occurs in acute kidney injury and plays a cytoprotective role. Biochim Biophys Acta. (2015) 1852:482–9. doi: 10.1016/j.bbadis.2014.12.013

61. Mustafa SA, Singh M, Suhail A, Mohapatra G, Verma S, Chakraverty D, et al. Sumoylation pathway alteration coupled with downregulation of sumo2 enzyme at mucosal epithelium modulates inflammation in inflammatory bowel disease. Open Biol. (2017) 7:170024. doi: 10.1098/rsbm.20170024

62. Fritah S, Lhocine N, Golebiowski F, Mounier J, Andrieux A, Jouvin G, et al. Sumoylation controls host anti-bacterial response to the
gut invasive pathogen shigella flexneri. EMBO Rep. (2014) 15:965–72. doi: 10.15252/embr.201338386

84. Bossis G, Malnou CE, Farras R, Andermarcher E, Hipskind R, Rodriguez M, et al. Down-regulation of c-fos/c-jun ap-1 dimer activity by sumoylation. Mol Cell Biol. (2005) 25:6964–79. doi: 10.1128/MCB.25.16.6964-6979.2005

85. Choi SJ, Chung SS, Rho EJ, Lee JW, Lee MH, Choi HS, et al. Negative modulation of reralpha transcriptional activity by small ubiquitin-related modifier (sumo) modification and its reversal by sumo-specific protease susp1. J Biol Chem. (2006) 281:30669–77. doi: 10.1074/jbc.M60403200

86. Ribet D, Hamon M, Gouin E, Nahori MA, Impens F, Neyret-Kahn H, et al. Listeria monocytogenes impairs sumoylation for efficient infection. Nature. (2010) 464:1192–5. doi: 10.1038/nature08963

87. Lapaquette P, Fritah S, Lhocine N, Andrieux A, Nigro G, Mounier J, et al. Shigella entry unveils a calcium/calpain-dependent mechanism for inhibiting sumoylation. Elife. (2017) 6:27444. doi: 10.7554/eLife.27444

88. Verma S, Mohapatra G, Ahmad SM, Rana S, Jain S, Khalsa JK, et al. Salmonella engages host micrornas to modulate sumoylation: a new arsenal for intracellular survival. Mol Cell Biol. (2015) 35:2932–46. doi: 10.1128/MCB.00397-15

89. Srikanth CV, Verma S. Sumoylation as an integral mechanism in bacterial infection and disease progression. Adv Exp Med Biol. (2017) 963:389–408. doi: 10.1007/978-3-319-50044-7_22

90. El Motiam A, Vital S, Sesane R, Bouzaher YH, Gonzalez-Santamaria J, Rivas C. Sumo and cytoplasmic rna viruses: from enemies to best friends. Adv Exp Med Biol. (2020) 1233:263–77. doi: 10.1007/978-3-030-38266-7_11

91. Sahu MS, Patra S, Kumar K, Kaur R. Sumoylation in human pathogenic fungi: role in physiology and virulence. J Fungi (Basel). (2020) 6:32. doi: 10.3390/jof6010032

92. El-Asmi F, McManus FP, Thibault P, Chelbi-Alix MK. Interferon, restriction factors and sumo pathways. Cytokine Growth Factor Rev. (2020) 55:37–47. doi: 10.1016/j.cytogfr.2020.03.001

93. Crowl JT, Stetson DB. Sumo2 and sumo3 redundantly prevent a noncanonical type i interferon response. Proc Natl Acad Sci USA. (2018) 115:6798–803. doi: 10.1073/pnas.1802114115

94. Yu S, Galeffi F, Rodriguiz RM, Wang Z, Shen Y, Lyu J, et al. Small ubiquitin-like modifier 2 (sumo2) is critical for memory processes in mice. FASEB J. (2020) 34:14730–67. doi: 10.1096/fj.202000850RR

95. Yang Y, Xia Z, Wang X, Zhao X, Sheng Z, Ye Y, et al. Small-molecule inhibitors targeting protein sumoylation as novel anticancer compounds. Mol Pharmacol. (2018) 94:885–94. doi: 10.1124/mol.118.112300

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Karhausen, Ulloa and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.